Vir Biotechnology (VIR) Stock Surges on Astellas Deal and Earnings Beat
Vir Biotechnology shares soared to a 52-week high following a strategic partnership with Astellas Pharma and stronger-than-expected quarterly results. The $1.7 billion deal centers on prostate cancer treatment VIR-5500, with $335 million in immediate payments and substantial milestone potential.
Early clinical data showed promising efficacy, with an 82% PSA50 decline rate in high-dose cohorts. The company's Q4 performance exceeded analyst expectations, posting revenue of $64.07 million against projections of $23.18 million.
Wall Street responded with bullish upgrades, including Raymond James raising its price target to $19 and Evercore ISI increasing its outlook to $18. The stock's 60% premarket surge reflects renewed confidence in Vir's oncology pipeline and financial trajectory.
